Eurosurveillance remains in the updated list of the Directory of Open Access Journals (DOAJ). It was first added to the DOAJ on 9 September 2004. Eurosurveillance is also listed in the Securing a Hybrid Environment for Research Preservation and Access / Rights MEtadata for Open archiving (SHERPA/RoMEO) [2], a database which uses a colour‐coding scheme to classify publishers according to their self‐archiving policy and to show the copyright and open access self-archiving policies of academic journals. Eurosurveillance is listed there as a ‘green’ journal, which means that authors can archive pre-print (i.e. pre-refereeing), post-print (i.e. final draft post-refereeing) and archive the publisher's version/PDF.

ESCAIDE participants are invited to the fifth Eurosurveillance scientific seminar on 30 November 2016

Follow Eurosurveillance on Twitter: @Eurosurveillanc

Read our articles on Zika virus infection

Read our articles on mcr-1-mediated colistin resistance

Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015. Available from: / ViewArticle.aspx?ArticleId=21169

In this issue

Home Eurosurveillance Monthly Release  2006: Volume 11/ Issue 7 Article 2
Back to Table of Contents
en es fr

Eurosurveillance, Volume 11, Issue 7, 01 July 2006
Outbreak report
Brote prolongado de enfermedades meningocócicas B en Seine Maritime, Francia, enero 2003 a junio 2005

Citation style for this article: Rouaud P, Perrocheau A, Taha MK, Sesboué C, Forgues AM, Parent du Châtelet I, Lévy-Bruhl D. Brote prolongado de enfermedades meningocócicas B en Seine Maritime, Francia, enero 2003 a junio 2005. Euro Surveill. 2006;11(7):pii=635. Available online:


P Rouaud1, A Perrocheau2, MK Taha3, C Sesboué4, A Forgues4, I Parent du Châtelet2, D Lévy-Bruhl2
1. Cellule inter régionale d’épidémiologie de Haute-Normandie, Rouen, Francia
2. Institut de veille sanitaire, Saint Maurice, Francia
3. Centre national de référence des méningocoques, Paris,Francia
4. Direction Départementale des Affaires Sanitaires et Sociales de Seine-Maritime, Rouen, Francia


Entre enero de 2003 y junio de 2005, se produjo un brote prolongado de enfermedades meningocócicas en el distrito de Seine-Maritime en Francia. Se declararon 86 casos, dando una incidencia media anual de 2,7 casos por 100.000 habitantes, comparado con una incidencia anual nacional de 1,6. Se identificó un área especialmente afectada, que incluía la ciudad de Dieppe y sus alrededores (26 casos, con una incidencia anual de 12 casos por 100.000). Este brote era debido a N. meningitidis fenotipo B:14:P1.7,16 perteneciente al complejo clonal ST-32/ET-5. Se confirmaron por fenotipado 31 casos de B14:P1.7,16 en el Centro Nacional de Referencia de Meningococos (CNR), asociados a una tasa de mortalidad (19%) y una proporción de purpura fulminans (42%) particularmente altas. Los grupos de edad más afectados fueron los jóvenes de 15 a 19 años y los niños entre uno y nueve años. En 2003, las autoridades sanitarias llevaron a cabo una vigilancia epidemiológica reforzada, junto con campañas de información hacia los médicos y el público. En 2004, el comité nacional de vacunaciones evaluó la oportunidad de utilizar una vacuna no autorizada, basada en vesículas de membranas externas de N. meningitis B y desarrollada en Noruega, que podría proporcionar protección contra la cepa B14:P1.7,16. En 2006, el Ministerio de Sanidad decide proponer la vacunación con dicha vacuna en las personas entre uno y 19 años en Seine Maritime.
El artículo completo está disponible en inglés



Back to Table of Contents
en es fr

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN 1560-7917] - ©2007-2016. All rights reserved.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.